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Background: The isolation of recombinant antibody fragments from displayed libraries represents a powerful
alternative to the generation of IgGs using hybridoma technology. The selected antibody fragments can then be
easily engineered into (multi)-tagged constructs of variable mass and complexity as well as reconstituted into
Camelidae IgG-like molecules when expressed fused to Fc domains. Nevertheless, all antibody constructs depend
on an oxidizing environment for correct folding and consequently still belong to the proteins difficult to express in
bacteria. In such organisms they are mostly produced at low yields in the periplasmic space.
Results: We demonstrate that fusion constructs of recombinant antibodies in combination with multiple tags can
be produced at high yields and totally functional in the cytoplasm of bacteria expressing sulfhydryl oxidase. The
method was applied to structurally demanding molecules such as VHHs fused to SNAP and Fc domains and was
validated using the antibody-derived reagents in a variety of immune techniques (FACS, ELISA, WB, IP, SPR, and IF).
Conclusions: The collected data demonstrate the feasibility of a method that establishes a totally new approach
for producing rapidly and inexpensively functional Camelidae IgG-like monoclonal antibodies and antibody-based
reagents containing multiple disulfide bonds and suitable for both basic research and clinical applications.
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Monoclonal antibodies are probably the most versatile
and widespread class of reagents used in biology research,
diagnostics, and therapy. Although IgG antibodies recov-
ered from hybridoma cells still dominate the field, alterna-
tive formats know a constantly increasing success and
recombinant Fab, single-chain (scFv) and single-domain
(VHH) antibodies have demonstrated their reliability in
basic research as well as in clinical applications [1,2]. In the
case of VHHs, their reduced mass is a decisive advantage* Correspondence: Ario.de-marco@curie.fr
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unless otherwise stated.to obtain faster clearance for in vivo imaging, a better pene-
tration in solid tumors and even the permeation across the
blood brain barrier [3-5]. The in vitro selection allows for
the isolation of binders for toxic or scarcely antigenic tar-
gets as well as for epitopes correlated to specific functions.
Whole cells have been successfully used for panning anti-
body fragments that recognize membrane proteins in their
native membrane environment and for identifying new
biomarkers [6]. Basic molecular biology techniques allows
for VHH fusion to tags and larger carriers to obtain
application-optimized reagents [7]. Single-domains can be
easily reconstituted into the Camelidae IgG-like format by
fusion to a Fc domain and Fc moieties with different char-
acteristics can be selected to tune ADCC and CDC effects
in different organisms.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Yield comparison of anti-HER2 VHHs fused
together to different tags
A10 mg/L C8 mg/L G3 mg/L
Myc per IMAC 1-5 1-5 <1
Myc per SEC 1-2 <1 <0.5
SNAP cyt IMAC 15-20 20-25 10-15
SNAP cyt SEC 15-20 20-25 10-15
SORT-Tag cyt IMAC 6-8 4-7 4-7
SORT-Tag cyt SEC 4-6 3-5 3-5
SORT-Tag per IMAC <0.1 <0.1 <0.1
Fc cyt IMAC 25-30 10-15 15-20
Fc cyt SEC 25-30 10-15 10-15
The recombinant antibodies were cloned in vectors that promote either
periplasmic (per) or cytoplasmic (cyt) accumulation and folding, expressed in
bacteria, and finally purified by metal affinity chromatography (IMAC) followed
by gel filtration (Size Exclusion Chomatography - SEC). The yields are
expressed in mg/L of culture and indicate the range obtained in at least three
independent purification procedures.
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bodies are routinely expressed also in prokaryotic systems.
Bacteria can be used to display on their surface antibodies
of different format for diagnostic applications [8,9] and to
obtain elevated VHH productions in both the periplasm
and the cytoplasm [10-13]. In contrast, the yields of recon-
stituted IgG-like molecules and fusions with some valuable
tags remain low [14,15] due to either structural complexity
or different redox requirements of the two partner polypep-
tides. Recently, it has been demonstrated that the cytoplas-
mic co-expression of disulfide-bond dependent proteins
together with sulfhydryl oxidase and a disulfide bond isom-
erase increased significantly the production of the target
proteins [16]. Such approach proved being effective to
improve the cytoplasmic accumulation of full-length
VHH-SNAP tag fusions [17]. Nevertheless, no proof of
antibody functionality was shown in this preliminary
communication. Now we demonstrate that several VHH-
based constructs as complex as the IgG-like reconstituted
VHH-Fc antibodies can be produced in bacterial cytoplasm
at elevated yields and preserve their complete functionality.
This opportunity represents a time and cost effective
alternative to the conventional expression of IgG anti-
bodies from hybridoma cells. Furthermore, it allows the
production of fusion molecules such as the VHH-SNAP
or VHH-GFP constructs that are difficult to obtain in
oxidizing environments.
Results and discussion
The in vitro recovery of recombinant antibodies represents
an effective and rapid alternative for isolating binders
against any antigen class. Furthermore, the access to the
antibody sequence simplifies molecular engineering and
opens the possibility to fuse suitable tags to the anti-
bodies to develop them in reagents optimally suited to
different applications. Such fusion constructs are often
easy to produce in bacteria and we designed a collection
of vectors for the parallel expression of application-
friendly VHHs production in both bacterial periplasm
and cytoplasm (Additional file 1: Figure S1). In a prelimin-
ary expression test we noticed that tags could significantly
modify the antibody stability and yields. SNAP/CLIP and
GFP were poorly folded and were prone to aggregate when
expressed in the periplasm whereas the presence of trans
disulfide bonds in structurally complex proteins such as
alkaline phosphatase, peroxidases, and enzymatic toxins
seemed to be compatible only with periplasmic expres-
sion. We designed a decision chart with the aim of opti-
mizing the cytoplasmic expression of fusion antibodies
that either failed to be expressed in the periplasm or,
such as the Fc-fusions, accumulated in low amounts
(Additional file 2: Figure S2). Bacterial mutants in which
the cytoplasmic reducing metabolism is impaired have been
sometimes successfully used to express disulfide-dependentproteins but the results are contradictory specially when
molecules with multiple disulfide bonds must be produced
[11,18]. Therefore, we evaluated the promising alternative
of inducing the formation of disulfide bonds in the
cytoplasm of wild type bacteria in which a recombinant
eukaryotic sulfhydryl oxidase is accumulated [16]. The
expression of the oxidizing enzyme is triggered by ara-
binose addition to the culture medium and can be in-
duced independently and before the expression of the
antibodies by means of IPTG addition.
By panning a pre-immune library, we isolated several
VHHs specific for the ectodomain of the human HER2
receptor (data not shown) and expressed three of them
(A10, C8, G3) using both the original periplasmic phagmid
vector (pHEN2) which allows for the fusion to a His-myc
tag and a cytoplasmic vector (pSNAP) for obtaining a
His-SNAP fusion. The constructs were purified by IMAC
and successively by gel filtration for separating aggregates
and polymerization products (Additional file 3: Figure S3a).
The yields of the SNAP-fusions were significantly higher
than those of the myc-fusions (Table 1) and the degradation
products/aggregates represented a negligible percentage of
the affinity-purified antibodies (Figure 1 and Additional file
3: Figure S3a). We then compared the performance of the
constructs expressed in the periplasm (His-myc, per) and
cytoplasm (His-SNAP, cyt) at the FACS. In a first experi-
ment, the detection was obtained in both cases using an
anti-His labeled secondary antibody (indirect labeling).
The A10-SNAP construct discriminated the HER2-positive
SKBR3 and MCF10A negative cell populations even better
than the A10-myc (Figure 1). However, the advantage of
the SNAP tag is that it can be covalently labeled before im-
mune detection (FACS or IF) enabling the direct detection
of the antigen. The construct A10-SNAP coupled to the
chromophore SNAP-Surface 549 successfully identified its
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Figure 1 Functional validation of the anti-HER2 SNAP-tagged VHH A10 expressed in the bacterial cytoplasm. Cytoplasmic-expressed
A10-SNAP fusion protein was eluted at almost homogeneity (E) after a single metal affinity chromatographic (IMAC) step. Both a portion of the
fusion protein and SNAP alone accumulated in the pellet (P). FACS analysis (filter band-pass: 564-606 nm) was performed using HER2 negative
(MCF10A) and positive (SKBR3) cells and used to compare different A10 constructs and detection methods: i) myc + His-tagged antibodies
expressed in bacterial periplasm in combination with anti-His and a secondary antibodies; ii) SNAP + His-tagged antibody expressed in bacterial
cytoplasm in combination with anti-His plus secondary antibody; iii) SNAP + His-tagged antibody expressed in bacterial cytoplasm directly linked
to the SNAP-Surface 549 (NEB) chromophore. The same cell lines were used in combination with A10-SNAP for cell ELISA and for immunostaining
HER2 at the cell membrane of negative (MCF10A) and positive (SKBR3) cells.
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clone fused to SNAP showed specificity in cell ELISA and
in immunofluorescence when HER2-positive SKBR3 and
HER2-negative MCF10A cells were compared (Figure 1).
A10 myc and SNAP constructs showed comparable SPR-
measured affinities for the purified ectodomain of HER2, a
further clear indication that the cytoplasmic expression
did not decrease the functionality of the recombinant
antibody fused to the SNAP tag (Figure 2a). This first
set of results demonstrated that the cytoplasmic expression
of VHH-SNAP fusions in the presence of sulfhydryl oxidase
enabled to produce functional antibodies the binding
capacity of which was at least as good as that of the
same VHHs expressed in the periplasm, but with sig-
nificantly higher yields. Similarly, we successfully
expressed, labeled, and validated by FACS a scFv-SNAP
construct (anti-claudin-3, Additional file 4: Figure S4a),
the A10 VHH fused to the tags CLIP and HALO
(Additional file 4: Figure S4b), and produced a VHH-GFP
fusion protein that provided a clear signal shift in flow cy-
tometry without the necessity of using primary/secondary
commercial antibodies (Figure 2b). Wild type GFP cannot
be exported to the periplasm by the SEC pathway in an
active form [19] and, although some fluorescent pro-
tein variants are able to accumulate in this oxidizing
cell compartment necessary for the formation of theantibody disulfide bonds, the choice remains limited to
few molecules [20,21]. Here we demonstrate the feasi-
bility of an approach to produce in the bacterial cyto-
plasm fluorescent immune reagents that should be not
restricted to few specific sequences.
In these first examples of cytoplasmic antibody expres-
sion, no direct comparison between the same construct
expressed either as cytoplasmic or secreted protein was
possible because we did not manage to recover soluble
VHH-GFP and VHH-SNAP fusion proteins from the
bacterial periplasm. Therefore, we used another tag
that could be expressed in both bacterial cell compartments
to obtain comparable samples. The SORT-tag is a short
peptide (LPTEG) that allows for the sortase-dependent
covalent conjugation to N-terminal available glycine
residue(s) [22] and has been used for obtaining fusions
between several classes of molecules [23,24]. Surprisingly,
the presence of this short tag instead of the conventional
myc strongly decreased the solubility of all three tested
anti-HER2 antibodies when they were expressed in the
periplasm (Table 1). In contrast, the cytoplasmic yields
were elevated and, in terms of molarity, comparable
with those obtained using SNAP as a fusion tag (Table 1).
The SORT-tagged antibodies produced in the periplasm
and in the cytoplasm labeled at similar intensity HER2
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Figure 2 Comparison between antibody constructs expressed in the bacterial cytoplasm and periplasm. a) The affinity of the VHH A10
for its antigen HER2 (purified ectodomain) was measured by Surface Plasmon Resonance. Three constructs were compared: A10 tagged myc + His
and expressed in the bacterial periplasm, A10 tagged SNAP + His and A10 tagged SORT + His, both expressed in the bacterial cytoplasm. The graphs
correspond to a single experiment representative of at least three repeats. The analyte concentrations were in the range 300-3.5 nM (myc-tag), 100-3.5 nM
(SNAP-tag), and 30-0.35 nM (SORT-tag). b) The anti-HER2 antibodies A10 fused to GFP was expressed in the cytoplasm and directly assessed
by FACS (filter band-pass: 515-545 nm) using HER2 negative (MCF10A) and positive (SKBR3) cells. c) The anti-HER2 antibodies A10 and C8
were expressed fused to the LPTEG peptide (SORT tag) in both the periplasm and the cytoplasm and the resulting samples were assessed
by FACS (filter band-pass: 564-606 nm) using HER2 negative (MCF10A) and positive (SKBR3) cells, and the 6xHis tag for visualization.
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structs (Figure 2c). Unexpectedly, the cytoplasmic
A10-SORT construct showed higher SPR-measured af-
finity for its antigen than the control A10-myc con-
struct recovered from the periplasm (Figure 2a). The
difference was totally due to the improved association
rate. This result confirmed the binding functionality of
the construct expressed in the cytoplasm and suggests
that despite having similar overall mass, the relative
length and/or folding of the different tags can influence
the accessibility and actual binding of the two constructs
to the antigen epitope, as already noticed by other authors
[25,26]. We cannot rule out that the small observed differ-
ences in terms of antibody binding capacity were due to
minimal stability variation of the different constructs. If this
is the case, cytoplasmic expression resulted more conveni-
ent than the periplasmic production of the same construct
because it enabled both higher yields and slightly but re-
peatedly measured “improved” functionality.
Recombinant antibodies with tags such as SNAP/CLIP/
HALO/GFP and SORT are suitable for several attractive
biological applications, but still represent a niche in com-
parison to IgG antibodies. In some cases, introducing newprotocols based on non-conventional antibody formats for
performing immunological analyses might be demanding
for the lab management. Therefore, it can be more practical
to reconstitute antibody fragments into IgG-like molecules
that can be used and detected as conventional monoclonal
antibodies. Consequently, we expressed in the cytoplasm
the same anti-HER2 set of antibodies used in the previous
experiments but as fusions with a rabbit Fc domain. This
tag offers some specific advantages such as the possibility
to affinity purify the molecules using Protein A/G, to in-
crease the avidity for the antigen by inducing dimerization,
and to perform multiple parallel staining by exploiting Fc
domains issued from different organisms [27].
All the constructs were well expressed (Table 1) and
highly pure already after IMAC step (Additional file 3:
Figure S3b). Size exclusion chromatography (SEC)
confirmed that the antibodies were monodispersed
(Additional file 3: Figure S3b). The functionality of the
bivalent Fc-VHHs was confirmed by cell ELISA and
FACS. In this last case, the reconstituted IgG-like
molecules were at least as effective as the therapeutic
antibody trastuzumab (Figure 3). Although VHHs usually
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Figure 3 Functional validation of Fc-VHH fusion antibodies. Fc-VHH constructs corresponding to the clones A10 and C8 were expressed in
the bacterial cytoplasm, purified, and finally tested by cell ELISA and compared with the monoclonal anti-HER2 therapeutic monoclonal antibody
trastuzumab by FACS (filter band-pass: 564-606 nm) using HER2 negative (MCF10A) and positive (SKBR3) cells. C8-Fc was used for HER2 detection
by WB and to immunoprecipitate HER2 from SKBR3 cells.
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total cell lysate and immunoprecipitated the full-length as
well as many of the shedding products [28] of the HER2
ectodomain (Figure 3). These results indicate that the
epitope recognized by the binder is probably very basal
and that C8 could be useful for evaluating the metal
protease-dependent HER2 isoform distribution in differ-
ent cell populations. The IF staining pattern on HER2
positive and negative cells was identical for the mono-
clonal trastuzumab, the cytoplasmic produced IgG-like
A10-Fc construct, and the monovalent periplasmic pro-
duced A10-myc construct (Figure 4).
The measurement of the apparent affinity (avidity) of
bivalent constructs confirmed that the tag characteristics
can influence the antigen/antibody binding, as previously
observed for the monovalent constructs (Additional file 5:
Table S1). The avidity effect enabled the construct A10-Fc
to bind its antigen one log stronger (Figure 5) than the
monovalent constructs (Figure 2c). At the same time, there
is a substantial difference between the avidities of the Fc
and alkaline phosphatase (AP) fusions (Figure 5). Although
expressed in the periplasm, the dimer A10-AP bound HER2
with a KD in the lower nanomolar range, a log worse than
the A10-Fc construct produced in the cytoplasm (Figure 5).
This result confirms that functional binding capacity is not
a simple matter of active domain number [29].
Finally we evaluated the capacity of the IgG-like recon-
stituted antibodies produced in the bacterial cytoplasm totarget a HER2-positive tumor in vivo using a xenografted
murine model. C8 was preferred because it was the only
of the three characterized antibodies that worked in both
WB and IP and, therefore, we expected that it could
recognize its antigen in a wider range of structural confor-
mations. Animals were treated with infra-red labeled anti-
HER2 C8-Fc and trastuzumab (positive control), as well as
with an anti-GFP antibody (negative control). Tumors were
recovered after both 3 and 48 hours, sectioned along the
median axis to have access to the inner section, and the
emitted infrared fluorescence was recorded (Figure 6). The
mass (80 kDa) of reconstituted IgG-like Abs impairs direct
kidney filtration and the rapid clearence specific of mono-
valent VHHs (14 kDa) [5,30]. Consequently, C8-Fc accu-
mulated in the tumor tissues with the same kinetic of the
positive control trastuzumab. Although fluorescence does
not allow for accurate quantitative comparisons, the recom-
binant antibodies seem as effective as trastuzumab in con-
centrating inside the tumor. The tumors treated with the
control anti-GFP recombinant antibody did not show any
fluorescence signal at both 3 and 48 hours.
Conclusions
Single-domain antibodies can be produced at elevated
yields and their structural stability allows for the accu-
mulation of functional molecules even in the cytoplasm
of wild-type bacteria [13]. Here we show that even for-
mats as complex as Camelidae IgG-like structures can




Figure 4 Identification of the membrane receptor HER2 by immunofluorescence. The IF staining pattern of the VHH A10 fused to either











ka: 6.30 x106 1/Ms; kd: 8.21 x10-4 1/s; KD: 1.30 x10-10 M 





















Figure 5 Avidity effect of the bivalent Fc-VHH construct. The
avidity of the bivalent A10-Fc was compared with that of the bivalent
constructs A10-alkaline phosphatase (AP, periplasmic bacterial expression)
and trastuzumab (hybridoma expression). The graphs correspond to
a single experiment representative of at least three repeats. The
analyte concentrations were in the range 1-0.01 nM (myc-tag),
300-3.5 nM (AP-tag), and 1-0.01 nM (SORT-tag).
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Functional IgG recombinant antibodies have been
already successfully produced in bacterial periplasm in the
past [14] but yields of correctly assembled full-length
molecules rarely exceeded 1 mg/L when shake flasks were
used. This condition limited antibody discovery programs
that rely on the availability of large batches of antibodies.























Figure 6 Antibody accumulation in xenografted tumors. HER2
positive tumors were recovered from treated mice 3 and 48 hours after
antibody injection. Tumors were cut in two pieces along their median
axis and their infrared fluorescence intensity detected at 770 nm.
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ceeded in yielding up to 4 mg/L of IgGs [15] and simi-
lar yields were obtained expressing scFv-Fc fusions in
Leishmania tarantolae [31]. The protocol described in
this article shows that it is possible to increase the
yields to tens of mg/L and, according to recently pub-
lished data [13], there is still the possibility to enhance
the yields per liter of culture by increasing the cell dens-
ity using optimized media and fermentation conditions.
However, the main achievement of our approach is the
demonstration –obtained by means of several independent
techniques [32]- that the functionality of the IgG-like
constructs is totally preserved when they are purified after
expression in the cytoplasm of bacteria co-expressing
sulfhydryl oxidase and the bacterial protein disulfide
isomerase DsbC. The combined oxidative and isomerase
activities apparently prevent the accumulation of non-
functional antibodies. When the comparison was possible,
the constructs expressed in the cytoplasm showed both
lower aggregation and degradation than those measured
in the periplasm. This approach, initially proposed by
Ruddock’s group for producing disulfide-bond dependent
secreted proteins [16,33], perfectly fits to antibody frag-
ments fused to tags with different folding requirements
[17,34]. The bottleneck represented by the saturation of
the SEC-translocon [35] would explain the remarkable
higher yields obtained when the antibodies were produced
in the cytoplasm rather than in the periplasm. Lately
we expressed tens of other VHH-Fc constructs using
both rabbit and human Fc and clearly remarked yield
difference among antibodies. This condition is probably
due to the intrinsic stability of the different sequences but
the cytoplasmic expression was constantly more productive
than the periplasmic.
The present trend in both academic and industrial labs
seems to be focused on using single domain antibodies
from Camelidae and human origin as well as Fab fragments
to identify new reagents and therapeutic molecules [36,37].
We believe that our approach might represent a break-
through technology for researchers who need to produce
significant amounts of antibodies and antibody-based re-
agents for preliminary in vitro and in vivo characterization.
We produced the described antibodies in wild type E. coli
that cannot provide eukaryotic-like glycosylation but our
results should encourage expressing IgG-like constructs in
modified bacteria [38] with the aim of obtaining antibodies
with native post-translational modifications.
Methods
Plasmid preparation
pET14b-rFc. The rabbit Fc fragment of the pFUSE-rFc2-
adapt-scFv vector [39] was amplified by PCR using forward
primer GAGGCGGCCGCTAGATCTAGCAAGCCCA
CGTG and backward primer GAGATTGGATCCATCATGTCTGGCCAGCTAGC. The PCR product was purified
by agarose gel electrophoresis and sub-cloned into pET14b-
hFc-multitag between NotI and BamHI. VHHs were then
inserted in pET14b-rFc between NcoI and NotI.
pSORTp. The DNA sequence corresponding to GSSGG-
LPETG-6xHis was synthesized by Proteogenix (France) and
sub-cloned into the pHEN8 [40] vector using NotI and
BsmI. VHHs were then inserted in pSORTp between NcoI
and NotI. The sequence of the VHH-GSSGG-LPETG-
6xHis in the pSORTp vector was digested with NcoI
and BamHI and sub-cloned into pET14b to obtain the
cytoplasmic version of the vector (pSORTc).
The vector for the production of VHH and scFv anti-
bodies fused to the SNAP tag used in this work is identical
to the one described previously [7], but the lecture
frame has been modified by introducing a further base
to render it universal. CLIP and HALO sequences were
substituted to SNAP sequence to yield the corresponding
expression vectors.
Antibody production
Recombinant antibodies were expressed in E. coli BL21
(DE3) strain transformed with a plasmid for the expression
of sulfhydryl oxidase and DsbC [16,17]. Briefly, 2 mL of
over-night preculture were used to inoculate 500 mL of LB
broth in the presence of the appropriate antibiotics. For
small-scale screening purpose, 30 μL were used to inoculate
3 mL of culture medium. Bacteria were grown at 37°C
until OD600nm reached 0.4. Sulfhydryl oxidase and DsbC
expression was induced by adding 0.5% (g/mL culture)
of arabinose and the temperature was lowered to 30°C.
After 45 min, 0.05 mM of IPTG were added to induce
antibody expression, the bacteria were grown overnight
at 20°C, harvested, and frozen. Pellets were resus-
pended in 20 mL of 100 mM Tris pH8, 500 mM NaCl,
2.5 mM MgCl2. Lysozyme (0,5 mg/mL) and DNase
(3U) were added and the lysate was kept 30 min at
room temperature. Samples were sonicated and finally
centrifuged at 18,000xg for 20 min at 4°C. Lysates were
filtered and applied on either a HiTrap TALON® 5 mL
column or on a HiTrap MabSelect SuRe 5 mL column
in combination with a chromatographic AKTA pure
system (GE Healthcare). Analytical [41] and preparative
size exclusion chromatographic steps were performed
on Superdex™ 75 5/150 and 10/300 GL, respectively
(GE Healthcare). Antibody concentration was measured
using BCA colorimetric assay. Denaturing SDS-PAGE
gels (15%) were Coomassie stained and recorded using a
Gel Doc™ EZ System (Bio Rad). In the case of small-
scale production, the supernatant obtained after pellet
lysis was incubated in the presence of Protein A sephar-
ose beads (GE Healthcare), the beads were washed, re-
suspended in loading buffer, and the proteins separated
by denaturing SDS-PAGE.
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Cell lysates were separated on a 12% SDS-PAGE and
transferred to a nitrocellulose membrane. After 60 min
in 5% milk-PBS, the membrane was incubated 1 h with
10 μg/mL of the C8-Fc (IgG-like) antibody specific for the
HER2 ectodomain. After 3 washing steps in PBS, 4 μg/mL
of anti-myc monoclonal Ab (9E10) were added followed by
HRP-conjugated goat anti-mouse antibody (Cat. N. 32430,
Pierce). HRP-dependent signal was identified by autoradi-
ography using enhanced chemiluminescence.
For immunoprecipitation (IP), SKBR-3 cells were grown
to 90% confluence in 150 mm culture dishes, washed twice
with PBS, and their lysis was induced in the presence of
3 mL of 10 mM Tris–HCl, pH 8.0, 150 mM NaCl, 1% NP
40, 1 mM EDTA, protease inhibitor cocktail for each dish.
After 1 h incubation at 4°C, the material was harvested by
scraping and cell debris was separated from soluble lysate
by centrifugation (10 min at 3600xg and 4°C). All the incu-
bation steps were performed rocking the tubes constantly.
Cleared cell lysates (5 mL) resuspend in an equal volume of
IP buffer (10 mM Tris–HCl, pH 8.0, 150 mM NaCl, 1%
NP40) were pre-incubated 1 h at 4°C in the presence of
200 μL of protein G agarose beads (Thermo Fisher) and
successively washed 3 times in IP buffer to eliminate unspe-
cific binding. The supernatant was recovered by centrifuga-
tion (3 min × 2500 g), mixed with 200 μg of the antibody,
and incubated 2 h at 4°C. Finally, 200 μL of washed protein
G agarose beads were added and washed after 1 h at 4°C 5
times in 10 mL of IP buffer five times before being resus-
pended in 50 μL of SDS loading buffer and heated 10 min
at 95°C. The protein samples were fractionated on a 12%
SDS-PAGE, transferred to a nitrocellulose membrane,
and HER2 was identified by chemiluminescence as for
the western blot.
Flow cytometry analysis
Specific antibody binding to the HER2 receptor expressed
at the cell surface was analyzed by flow cytometry using
SKBR3 (positive sample) and MCF10A (negative sample)
cells. Cells were first incubated in 96 well plates in the
presence of 10% FCS-PBS to prevent unspecific binding
and then 2 hours at 4°C cells with monovalent VHHs.
Cells were analyzed with FACS-Calibur Flow Cytometer
(BD Biosciences) after having incubated them 1 hour at
4°C with either a monoclonal anti-myc (9E10) or an
anti-His (Tebu Bio) primary antibody followed by a
goat anti-mouse antibody conjugated to phycoerythrin
(BD Pharmingen). SNAP-tag was directly labeled using
the chromophore SNAP-Surface AlexaFluor 549 (NEB).
The SNAP-Surface AlexaFluor 647 Protein Labeling
kit (NEB) was employed to label the scFvH6-SNAP fusion
protein according to the manufacturer’s instructions. Cell
surface claudin-3 specific binding was tested on native
unfixed OSPC-2 primary ovarian carcinoma cell line(positive sample) and human leukemia K562 cells (negative
control). After detachment with 0.5 mM EDTA, cell
viability was evaluated with Trypan Blue exclusion and
only samples with more than 80% of viable cells were
considered for staining. Membrane integrity of stained
samples was assessed with PE Annexin V Apoptosis
detection kit (BD Pharmingen) and AnnexinV negative
viable cells where identified with an appropriate gating
strategy. Approximately 2x105 cells per test were used
for each experiment. Cells were washed three times with
PSB buffer supplemented with 0.5% BSA and incubated
1 hour at 20°C with 500 ng of scFvH6-Alexa 647. Cells
were finally resuspended in PBS and analyzed by flow cy-
tometry using FACS-Calibur and Cell quest Pro Software
(BD). No commercial antibody for the claudin-3 ectodo-
main is available for direct comparison.
ELISA
Assays were performed in 96 well round bottom plates.
Wells were coated over-night at 4°C with either 5 μg/mL of
recombinant HER2-Fc or 8 μg/mL of rabbit-IgG (Sigma)
as a control. Wells were then saturated 2 hours at
room temperature with 3% BSA-PBS and recombinant
His-tagged VHHs were added at concentrations of 130
(Fc-constructs) and 303 (SNAP-constructs) nM. After
1 hour incubation at room temperature, the specific
signal was visualized by incubating the samples 1 hour
at room temperature in the presence of anti-His primary
antibody (Tebu Bio) followed by a goat anti-mouse con-
jugated to peroxidase (Pierce). The OD was measured at
450 nm. Cell ELISA with VHH-Fc was performed using
the same protocol and 105 cells in suspension/well instead
of purified HER2.
Surface plasmon resonance analysis
The affinity and avidity of the anti-HER2 constructs for their
substrate was measured at 25°C using a ProteOn XPR36
(BioRad). Fc-HER2 ectodomain produced in mammalian
cells (96 kDa) was diluted to 2 μg/mL in sodium acetate
buffer (pH 5.0) and immobilized by amine-coupling on
a GLC chip (BioRad) at 2000 RU. 100 μL of antibodies
were used as analyte and injected at 100 μL/min. The
complete kinetic data set for each antibody was col-
lected in a single run and fitted using a 1:1 Langmuir
interaction model. Surface regeneration was performed
using 10 mM glycine HCl, pH 2.0 (IgG-like format) or
3.0 (VHH format).
Immunofluorescence
MCF10A and SKBR3 cells were seeded on coverslips
overnight. The day after, cells were first incubated 15 min
at room temperature in 4% PFA-PBS and then 2 hours at
room temperature in the presence of the antibodies. Sam-
ples were incubated 45 min in the dark in the presence of
Djender et al. Microbial Cell Factories 2014, 13:140 Page 9 of 10
http://www.microbialcellfactories.com/content/13/1/140suitable Cy3-conjugated antibodies and finally mounted on
microscope slides by using Mowiol.
Tumor targeting in vivo
Trastuzumab, the C8 single-domain fused to rabbit Fc
(C8-Fc), and the anti-GFP control VHH were diluted to
1 mg/mL in PBS and incubated in the presence of CF770
NHS esters (IVIS Xenolight, Caliper) at a 7.2 dye-to-protein
molar ratio according to the manufacturer’s protocol.
Unreacted CF770 dye was removed by gel filtration
using a NanoSep vial (IVIS Xenolight, Caliper). Labeled
protein samples were stored in the dark at 4°C.
HER2 positive BC111 tumor model was grafted sub-
cutaneously into the interscapular fat pad of female
Swiss nude mice under anesthesia. Experimental protocol
and animal housing were performed according to in-
stitutional and French Ethics Committee guidelines
(Agreement B75-05-18, France). Xenografts of 0.6-1 mm
developed two months after grafting, mice were anaesthe-
tized with isoflurane and 25 (3 hour experiments) or 100 μg
(48 hour experiments) of CF770 labeled antibodies in a
total volume of 100 μL were injected intravenously in the
tail vein. Infra-red fluorescence images were acquired using
IVIS Spectrum equipment and analyzed with Living Image
3.2 software (Caliper Life Sciences).
Additional files
Additional file 1: Figure S1. Application-friendly vectors for
single-domain antibody expression. The vector set provides the possibility
to fuse any antibody originated from a pHEN2 library to a double tag
(6 x His plus specific tag) suitable for ad hoc applications. All the vectors
have a conserved NcoI-NotI cloning site. Some tags are compatible for
expression in both periplasm and cytoplasm whereas no conclusive data
are available for other tags for which either cytoplasmic or periplasmic
expression have been confirmed so far. SNAP (human O6-alkylguanine-DNA
alkyltransferase); CLIP (modifid human O6-alkylguanine-DNA alkyltransferase);
HALO (modified haloalkane dehalogenase); GFP (green fluorescent protein);
SORT (amino acid sequence LPTEG for sortase-mediated covalent binding);
BS (biotinylation sequence); cys (free cysteine for maleimide reactions);
C-tag (amino acid sequence EPEA); Fc (Fc-domains, in our case rabbit and
human subtype IgG2); toxin (any secreted toxin); AP (alkaline phosphatase);
POX (peroxidase).
Additional file 2: Figure S2. Production flow-chart for the different
recombinant antibody constructs. According to the vector used for
cloning, the plasmids conceived for producing tagged antibodies are
transformed in E. coli strains with suitable features and the corresponding
antibodies will accumulate either in the bacterial cytoplasm or periplasm.
Lack of transformation can be the consequence of poor cell competence
or misuse of the selection antibiotics (ABs). Colonies of transformed cells
are used for both pre-culture inoculation and the preparation of glycerol
stocks. Cytoplasmic expression is performed in bacteria co-expressing
sulfhydryl oxidase and DsbC isomerase under the control of arabinose
and the production of these folding-support enzymes is triggered before
the IPTG-dependent expression of the target antibody. Periplasmic
expression is performed in shorter time to prevent excessive product
leakage into the culture medium. The addition of glucose is intended to
suppress basal expression and high IPTG concentrations should enable
rapid saturation of the expression machinery.
Additional file 3: Figure S3. Quality control of the SNAP- and
Fc-tagged anti-HER2 VHHs produced in the cytoplasm. SNAP-taggedantibodies were first affinity-purified by IMAC and their polydispersity was
successively evaluated by analytical Size Extrusion Chromatography (SEC).
The black bar corresponds to the exclusion volume. The proteins recovered
in the fractions were finally separated by SDS-PAGE and visualized using
colloidal blue. The A10 construct has been reported as an example.a)
Fc-tagged antibodies were first expressed and purified in small-scale to
assess the protein accumulation in the lysates (L) and bound to the beads
after washing (B). Numbering indicates either contemporary expression
induction of Fc-VHH and sulfhydryl oxidase (1) or to anticipated sulfhydryl
oxidase expression (2). For large-scale production, the constructs were
affinity-purified using Protein A and their polydispersity was successively
evaluated by analytical SEC. The black bar corresponds to the exclusion
volume. The protein was visualized after SDS-PAGE separation. The A10 and
C8 constructs have been reported as examples.
Additional file 4: Figure S4. Expression of fusion immunoreagents
composed of antibody fragments and SNAP, CLIP, and HALO tags. a) The
H6 scFv antibody specific for claudin-3 was fused to the SNAP-tag and
the resulting construct labeled with Alexa 647 before FACS analysis
(filter band-pass: 653-669 nm) using unfixed human ovary cancer line
OSPC-2 that expresses claudin-3 and K562 cells as a negative control. Green
lines indicate the level of reactivity of the scFvH6-SNAP, gray lines represent
cells in the absence of the antibody. Percentage of claudin-3 postive cells is
reported in each plot. b) Fusions of CLIP and HALO tags with the anti-HER2
A10 VHH were analyzed by FACS (filter band-pass: 564-606 nm) to assess
their binding to HER2 negative (MCF10A) and positive (SKBR3) cells.
Additional file 5: Table S1. Kinetic constants of fusion constructs formed
by the VHH A10 and different tags for their common antigen HER2.
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